With one in four American adults suffering from chronic knee pain, a promising study out of UCLA points to a viable, non-surgical solution: GDEFY® medically engineered shoes. In fact, study participants wearing the GDEFY shoes with patented VersoShock® technology reported an average reduction in knee pain of 85%, as well as significant decreases in other common conditions including back, ankle, and foot pain.
A double-blind, randomized study conducted at Olive View UCLA Medical Center, recently published in the Journal of the American Podiatric Medical Association, shows wearing shoes with VersoShock soles decreases knee pain by up to 85% vs. wearing shoes with conventional soles during prolonged standing and walking.
“Our mission is to maximize comfort and boost performance for people who have foot biomechanics that keep them from walking properly, and to enable normal pronation (foot movement),” said Alexander Elnekaveh, founder and Executive Chairman of Gravity Defyer Medical Technology Corporation, GDEFY’s parent company. “The goal is to ensure our customers can lead productive, pain-free lives anywhere—on the go or in the workplace.”
In the UCLA study, fifty-two adults with overuse symptoms of knee pain were enrolled and randomly assigned to use the intervention sole or the traditional sole shoes. For five weeks, participants wore either the shoe with the intervention sole or the shoe with the conventional sole, rating their knee pain on a 10-point visual analog scale at study onset, midway, and study completion.
After five weeks, participants using the GDEFY intervention sole shoe with shock-absorbing VersoShock technology reported an average reduction in knee pain of 85%, significantly better than participants using the traditional sole shoe (P < .01), whose average pain scores increased. Also observed were positive effects on back, ankle, and foot pain in those with the intervention sole shoe compared with the traditional sole shoe.
“We are committed to helping individuals stay active and pain-free. And the UCLA study proves that our powerful VersoShock technology significantly relieves discomfort,” said Elnekaveh.
This article is based on a press release from the Gravity Defyer Medical Technology Corporation.